SONORX
LOE ApproachingNDAORALSUSPENSION
Approved
Oct 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SONORX is an oral suspension approved in 1998 by Bracco Diagnostics for diagnostic imaging purposes. The mechanism of action and specific indications are not publicly detailed in available data, limiting assessment of clinical positioning.
LOE Approaching
Product is in late-stage maturity with moderate competitive pressure (30/100), indicating defensive commercial strategy focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SONORX presents limited career growth opportunities given its LOE-approaching status and zero linked job openings. Career progression is constrained by mature product lifecycle focused on retention and operational efficiency.
Brand ManagerField Sales Representative
Worked on SONORX at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.